Thrivent Financial for Lutherans boosted its holdings in Bath & Body Works, Inc. (NYSE:BBWI - Free Report) by 67.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 293,466 shares of the company's stock after acquiring an additional 118,165 shares during the quarter. Thrivent Financial for Lutherans owned 0.14% of Bath & Body Works worth $11,377,000 at the end of the most recent quarter.
A number of other hedge funds have also added to or reduced their stakes in BBWI. PDS Planning Inc boosted its position in shares of Bath & Body Works by 7.9% during the fourth quarter. PDS Planning Inc now owns 15,606 shares of the company's stock valued at $605,000 after buying an additional 1,147 shares during the last quarter. Corient Private Wealth LLC boosted its holdings in Bath & Body Works by 25.8% during the 4th quarter. Corient Private Wealth LLC now owns 21,378 shares of the company's stock worth $829,000 after acquiring an additional 4,383 shares during the last quarter. Royce & Associates LP purchased a new position in Bath & Body Works during the 4th quarter worth $1,276,000. Natixis Advisors LLC grew its stake in shares of Bath & Body Works by 46.0% in the 4th quarter. Natixis Advisors LLC now owns 89,460 shares of the company's stock worth $3,468,000 after acquiring an additional 28,186 shares in the last quarter. Finally, Catalyst Funds Management Pty Ltd purchased a new stake in shares of Bath & Body Works in the fourth quarter valued at about $1,919,000. Institutional investors and hedge funds own 95.14% of the company's stock.
Bath & Body Works Stock Down 1.1 %
Shares of NYSE BBWI traded down $0.36 during trading hours on Wednesday, reaching $31.84. 4,626,176 shares of the stock traded hands, compared to its average volume of 4,272,099. The company's 50-day simple moving average is $35.52 and its two-hundred day simple moving average is $34.03. The company has a market capitalization of $6.82 billion, a P/E ratio of 7.77, a price-to-earnings-growth ratio of 0.92 and a beta of 1.89. Bath & Body Works, Inc. has a 52-week low of $26.21 and a 52-week high of $52.99.
Bath & Body Works (NYSE:BBWI - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported $2.09 earnings per share for the quarter, topping analysts' consensus estimates of $2.04 by $0.05. Bath & Body Works had a net margin of 12.43% and a negative return on equity of 44.03%. The firm had revenue of $2.79 billion during the quarter, compared to analyst estimates of $2.78 billion. As a group, sell-side analysts forecast that Bath & Body Works, Inc. will post 3.3 earnings per share for the current fiscal year.
Bath & Body Works declared that its board has approved a share buyback plan on Thursday, February 27th that permits the company to repurchase $500.00 million in shares. This repurchase authorization permits the company to buy up to 6.4% of its stock through open market purchases. Stock repurchase plans are often an indication that the company's leadership believes its stock is undervalued.
Bath & Body Works Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Friday, March 7th. Shareholders of record on Friday, February 21st were given a dividend of $0.20 per share. The ex-dividend date of this dividend was Friday, February 21st. This represents a $0.80 annualized dividend and a yield of 2.51%. Bath & Body Works's payout ratio is 21.98%.
Analysts Set New Price Targets
Several research analysts recently weighed in on the stock. Citigroup upgraded shares of Bath & Body Works from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $40.00 to $48.00 in a report on Friday, February 28th. Raymond James restated an "outperform" rating and issued a $46.00 target price (up from $42.00) on shares of Bath & Body Works in a research note on Tuesday, February 25th. Deutsche Bank Aktiengesellschaft increased their price target on Bath & Body Works from $51.00 to $52.00 and gave the stock a "buy" rating in a research note on Tuesday, November 26th. Argus reissued a "hold" rating on shares of Bath & Body Works in a report on Friday, January 10th. Finally, Robert W. Baird boosted their price objective on shares of Bath & Body Works from $45.00 to $47.00 and gave the company an "outperform" rating in a research note on Friday, February 28th. Five research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $45.06.
Check Out Our Latest Analysis on BBWI
Bath & Body Works Profile
(
Free Report)
Bath & Body Works, Inc is a specialty retailers and home to America's Favorite Fragrances, offering a breadth of exclusive fragrances for the body and home, including the selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap.
Further Reading
Before you consider Bath & Body Works, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bath & Body Works wasn't on the list.
While Bath & Body Works currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
